Search clinical trials for: Exudative Subfoveal Age Related Macular Degeneration with Subfoveal Choroidal Neovascularization

Total 295116 results

Eyetech Pharmaceuticals
Pfizer

Completed

Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)

Macular Degeneration
Eyetech Pharmaceuticals
Pfizer

Completed

Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)

Macular Degeneration

United States
Novartis Pharmaceuticals

Completed

Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration (nAMD)

India
Novartis Pharmaceuticals

Completed

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study (TALON Ext)

Neovascular Age-related Macular Degeneration

United States, Czechia, Italy, Taiwan, Australia, Israel, Belgium, France, Spain, Germany, Korea, Republic of, Portugal, Sweden, Netherlands, Malaysia, Switzerland
Ophthotech Corporation

Terminated

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

Age-Related Macular Degeneration

United States
Outlook Therapeutics, Inc.

Completed

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Age-related Macular Degeneration | Wet Macular Degeneration | Neovascular Age-related Macular Degeneration

United States
Outlook Therapeutics, Inc.

Completed

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Age-related Macular Degeneration | Wet Macular Degeneration | Neovascular Age-related Macular Degeneration

Australia
RXi Pharmaceuticals, Corp.

Unknown

Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD

Age-related Macular Degeneration | Subfoveal Choroidal Neovascularization | Subretinal Scarring | Subretinal Fibrosis

United States
Novartis

Completed

EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Age-Related Macular Degeneration | Choroidal Neovascularization

Taiwan, Korea, Republic of
Novartis

Completed

Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Subfoveal Choroidal Neovascularization (CNV) | Secondary to Age-related Macular Degeneration (AMD)

Germany, Belgium, Spain, Netherlands, United Kingdom, Hungary, Turkey, Israel, Portugal, Australia
Genentech, Inc.

Completed

A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

Macular Degeneration

United States
Allergan

Terminated

Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration

Age-Related Maculopathy | Subfoveal Choroidal Neovascularization

United States
Pfizer

Terminated

A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States, United Kingdom, Australia, Netherlands
Pfizer

Completed

Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration

Macular Degeneration

Japan
Novartis

Terminated

Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

Macular Degeneration | Choroidal Neovascularization

United Kingdom, Spain, Netherlands, Hungary, Italy, Denmark, Belgium, Austria, France, Germany, Poland, Switzerland
Novartis

Completed

Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization

Macular Degeneration | Choroidal Neovascularization

United States, Canada
Novartis

Completed

Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) (EXCITE)

Age Related Macular Degeneration

Switzerland
Novartis

Completed

Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)

Japan
Novartis

Completed

SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Age Related Macular Degeneration | Choroidal Neovascularization

Switzerland
Asociación para Evitar la Ceguera en México
Centro Medico Issemym

Unknown

Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization

Subfoveal Choroidal Neovascularization

Mexico
University Hospital, Basel, Switzerland

Completed

Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV

Age-Related Macular Degeneration | Choroidal Neovascularization

Switzerland
Novartis

Completed

Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) (ADVANCE)

Wet Age-Related Macular Degeneration

Australia, United States
Allergan
Sirna Therapeutics Inc.

Completed

A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

Age-Related Macular Degeneration | Choroidal Neovascularization

United States
Novartis

Completed

Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration

Age-Related Macular Degeneration (ARMD)

Switzerland
Control Delivery Systems
Bausch & Lomb Incorporated

Unknown

A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration

Macular Degeneration

United States
Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) (TALON)

Age-related Macular Degeneration

United States, Austria, Czechia, Italy, Taiwan, Belgium, Germany, Australia, Israel, Canada, France, Spain, Korea, Republic of, United Kingdom, Portugal, Netherlands, Sweden, Argentina, Malaysia, Switzerland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration (FALCON)

Age-related Macular Degeneration

Germany, Switzerland
Neurotech Pharmaceuticals

Terminated

Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Macular Degeneration

United States, Israel
Novartis Pharmaceuticals

Completed

Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre) (FLUID)

Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD

Australia
David M. Brown, M.D.
Genentech, Inc.

Terminated

A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial) (SAVE)

Macular Degeneration | Age Related Macular Degeneration | Wet Age-Related Macular Degeneration | Choroidal Neovascular Membrane | Subfoveal Neovascular Age-Related Macular Degeneration

United States
Lpath, Inc.

Completed

Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD (Nexus)

Exudative Age-related Macular Degeneration

United States
Pfizer

Completed

Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration

Macular Degeneration
University of Illinois at Chicago
ICON Bioscience Inc

Completed

20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) (20089/Combo)

Age-Related Macular Degeneration | Choroidal Neovascularization

United States
Università degli Studi di Brescia

Completed

Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration

Wet Macular Degeneration

Italy
New England Retina Associates

Completed

Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes

Age Related Macular Degeneration | Epiretinal Membrane
Alcon Research

Completed

An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD

Macular Degeneration | Maculopathy, Age-Related

United States
Alcon Research

Completed

Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)

Macular Degeneration | Age-Related Maculopathies | Age-Related Maculopathy | Maculopathies, Age-Related | Maculopathy, Age-Related
Oraya Therapeutics, Inc.

Unknown

Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

Eye Diseases | Age-Related Macular Degeneration | Macular Degeneration | Retinal Diseases | Wet Age-Related Macular Degeneration

Mexico
The New York Eye & Ear Infirmary
Genentech, Inc.

Unknown

Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy (FVF4193s)

Age Related Macular Degeneration

United States
Genaera Corporation

Terminated

A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration

Macular Degeneration

United States
Manhattan Eye, Ear & Throat Hospital
Alcon Research

Completed

Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.

Age-Related Macular Degenerations. | Subfoveal Neovascularization.

United States
University of Utah
National Eye Institute (NEI)

Recruiting

Impact of Non-Exudative Type 1 MNV on AMD Progression

Age-Related Macular Degeneration | Neovascularization, Choroidal

United States
Novartis Pharmaceuticals

Recruiting

Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PROUD)

Macular Polypoidal Choroidal Vasculopathy (PCV)

Korea, Republic of
AbbVie

Recruiting

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT)

CNV | AMD | nAMD | Wet Age-related Macular Degeneration | wAMD | WetAMD

United States, Puerto Rico, Canada
AbbVie

Recruiting

Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)

CNV | AMD | nAMD | Wet AMD | Wet Age-related Macular Degeneration | wAMD

United States
University of Iowa

Recruiting

MMP-9 Inhibition for Recalcitrant Wet AMD

Wet Age-related Macular Degeneration | Exudative Macular Degeneration

United States
Novartis Pharmaceuticals

Completed

Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab. (IMAGINE)

Neovascular Age-related Macular Degeneration

Italy
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

Age-Related Macular Degeneration

France, Israel, Italy, United States, Spain, Portugal, Germany, Austria, Canada, Czechia, Estonia, Latvia, Poland, Slovakia, Australia, Hungary, Croatia, Argentina, Finland, Brazil, Colombia, Norway
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Age-Related Macular Degeneration

Israel, United States, Germany, Denmark, France, Turkey, Hungary, Colombia, Australia, Argentina, Spain
Ophthotech Corporation

Terminated

Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD

Age-related Macular Degeneration

United States

3

Subscribe